05-20-2011 12:11 PM CET - Health & Medicine
Print PDF

Advantages of Administering Pain Drugs via Inhalation Go Beyond Convenience

Press release from: Greystone Research Associates

(Amherst, NH) – The challenges of delivering drugs for treating pain – particularly in compromised patients - are well-documented. To address the risk and compliance factors associated with the administration of pain drugs, developers and researchers have been investigating inhalation – intranasal as well as oral inhalation – as a way to mitigate several of these issues. The market for inhaled pain drugs is currently dominated by products designed for intranasal delivery. But a number of drugs indicated for pain that are formulated for oral inhalation are winding their way through the development pipeline.

The potential advantages of pain drug inhalation have this group of therapeutics well-positioned to benefit from a number of market trends. As aging populations and managed care initiatives drive growth in home health care and self-administration of drug therapies, inhaled medicine is increasingly being viewed as patient-friendly and cost-effective.

Increased incidence in the general population and evolving pain management initiatives will drive growth in the pain product segment, as shifting patient demographics in developed societies increase demand for palliative treatments for conditions that include both nociceptive and neuropathic pain. And controlling pain associated with cancer is now considered an essential part of the practice of oncology.

A new research study from Greystone Associates, Inhaled Pain Management: Products, Therapeutics, Markets and Forecasts, examines the factors creating opportunities for inhalable pain management products. It identifies the key players in this segment, describes the regulatory and industry environment, and assesses the dynamics of patient care that will affect market development. The report also includes forecasts for the growth of inhaled pain management products.

More information is available at www.greystoneassociates.org .

Source: Greystone Associates

About Greystone

Greystone Associates is a medical technology consulting firm focused on the areas of medical market strategy, product commercialization, venture development, and market research. We assist medical and healthcare market participants in achieving their business objectives through the creation of detailed development strategies, product commercialization programs, and comprehensive market and technology research and analysis. Our market research publications are designed, researched and written to provide timely and insightful information and data on focused market segments, with the aim of providing market participants with the essential knowledge to refine and execute their marketing plans and financial targets.


Mark Smith
Greystone Research Associates
98 Route 101A
Amherst, NH 03031 USA
Voice: 603-595-4340
Fax: 603-804-0466

This release was published on openPR.
News-ID: 175853
More releases More releases
Permanent link to this press release:

Please set a link in the press area of your homepage to this press release on openPR.
openPR disclaims liability for any content contained in this release.

You can edit or delete your press release here: